Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast cell targeted pipeline.

Celldex Therapeutics shares trade at US$32.43, with a year to date share price return of 20.07% and a 1 year total shareholder return of 58.20%. This suggests recent barzolvolimab and CDX-622 data are contributing to building momentum after weaker multi year returns.

If mast cell targeted drugs are on your radar, this is also a useful moment to look across the sector and see what else is developing in allergy and immunology via 41 healthcare AI stocks

With Celldex Therapeutics now valued at about US$2.5b and trading at US$32.43, the market has clearly reacted to barzolvolimab and CDX-622 progress. The key question is whether you are looking at an undervalued mast cell platform or a stock already pricing in future growth.

Price-to-Book of 5.6x: Is It Justified for Celldex Therapeutics?

Based on the latest data, Celldex Therapeutics trades on a P/B ratio of 5.6x, which looks rich when set against both peers and the wider US Biotechs industry.

P/B compares the company’s market value to its net assets on the balance sheet. A higher figure often reflects expectations for future value creation that is not yet visible in current equity. For Celldex Therapeutics, a 5.6x multiple means investors are paying several times the company’s book value for exposure to its mast cell focused pipeline.

Against that backdrop, the contrast is clear. Celldex Therapeutics is described as expensive on a P/B basis versus the peer average of 3.6x, and it also screens as expensive relative to the broader US Biotechs industry average of 2.4x. That gap suggests the market is assigning a premium to Celldex’s assets and prospects compared with similar companies in the sector.

Result: Price-to-book of 5.6x (OVERVALUED)

However, Celldex Therapeutics still faces key risks, including clinical trial setbacks in its mast cell programs and ongoing losses, with revenue of US$865k against net losses of US$283.6m.

Another View: Celldex Therapeutics Through a Cash Flow Lens

The earlier P/B check describes Celldex Therapeutics as expensive, but the SWS DCF model points in a different direction. With the stock at $32.43 and the model’s future cash flow value at $82.98, it appears significantly undervalued according to this framework.

For any reader comparing these two signals, the contrast is clear: one method highlights valuation risk, while the other suggests potential upside based on future cash flows. The core question is which set of assumptions about Celldex Therapeutics’ mast cell pipeline and cash generation potential you find more convincing.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around Celldex Therapeutics are clear, so treat this as your prompt to review the data now, weigh both sides, and see the full picture using the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Celldex Therapeutics?

If Celldex Therapeutics has your attention, do not stop there. Broaden your opportunity set and let data driven shortlists surface stocks you might otherwise miss.

• Scan for value focused opportunities that combine quality and attractive pricing by reviewing the 45 high quality undervalued stocks.
• Strengthen your income ideas with a curated set of high yield payers by checking the 8 dividend fortresses.
• Lower portfolio stress by focusing on stability and resilience with the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.